OraSure Technologies Pledges Support for National Black HIV/AIDS Awareness Day
February 07 2008 - 7:34AM
Business Wire
OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral
fluid diagnostics, today announced its support of National Black
HIV/AIDS Awareness Day (NBHAAD), through the distribution of
complimentary OraQuick ADVANCE� Rapid HIV-1/2 Antibody Test kits
and educational materials to more than 25 HIV testing sites across
the country, including state and city public health departments and
community-based organizations. The tests and materials will be
utilized in observance of NBHAAD on February 7, 2008, to encourage
African Americans to learn their HIV status. According to the
Centers for Disease Control and Prevention (CDC), even though
blacks account for approximately 13% of the U.S. population, they
account for about half (49%) of the people who get HIV and AIDS.
HIV/AIDS continues to be a leading cause of death among African
Americans in the United States according to the CDC. "OraSure is
committed to combating HIV/AIDS in the African American community
and we are proud to support National Black HIV AIDS Awareness Day,"
said Douglas A. Michels, OraSure's President and Chief Executive
Officer. "Knowing one�s HIV status is a critical first step to
getting individuals into care and stemming the spread of the
disease and we recognize that our test plays an important role in
empowering individuals to know their status.� Committed to working
collaboratively with local and national agencies to fight against
HIV/AIDS, OraSure is actively supporting over 25 testing and
education programs, including programs in New York, Georgia, Puerto
Rico, Washington D.C., and the U.S. Virgin Islands among others,
that urge people to learn their HIV status. The OraQuick ADVANCE�
Rapid HIV-1/2 Antibody Test, manufactured and sold by OraSure
Technologies, is the first and only U.S. Food and Drug
Administration ("FDA") approved and CLIA (Clinical Laboratory
Improvements Amendments Act of 1988) waived rapid point-of-care
test that can detect antibodies to both HIV-1 and HIV-2 in 20
minutes, using oral fluid, finger-stick or venipuncture whole blood
and plasma specimens. The mission of NBHAAD is to build the
capacity and increase awareness, participation and support for HIV
prevention, care and treatment among African Americans. The
observance is directed, planned and organized by the Strategic
Leadership Council, which partners with the CDC to mobilize
communities and address specific issues regarding local epidemics
and best practices that are science-based and will influence the
course of HIV in Black communities across the country. About
OraSure Technologies OraSure Technologies develops, manufactures
and markets oral fluid specimen collection devices using
proprietary oral fluid technologies, diagnostic products including
immunoassays and other in vitro diagnostic tests, and other medical
devices. These products are sold in the United States as well as
internationally to various clinical laboratories, hospitals,
clinics, community-based organizations and other public health
organizations, distributors, government agencies, physicians'
offices, and commercial and industrial entities. In addition,
OraSure sells products for the cryosurgical removal of common and
plantar warts in the over-the-counter or retail market in Mexico,
Canada, certain European countries, Australia and New Zealand, and
a product for the cryosurgical removal of common and plantar warts
and several other benign skin lesions to the professional or
physician office market in the United States and many foreign
countries. For more information on the Company, please go to
http://www.orasure.com.
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
OraSure Technologies (NASDAQ:OSUR)
Historical Stock Chart
From Jul 2023 to Jul 2024